Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632051 | 0.83 | ALDH1A1 (0.42) | PTGFRCCR1KDM4E | |
| SCHEMBL21632035 | 0.83 | CCR1 (0.36) | PTGFRCCR1FFAR1FFAR4CYP2D6 | |
| SCHEMBL21631935 | 0.82 | PTGFR (0.33) | PTGFRCYP2D6CA1CA2 | |
| SCHEMBL21656305 | 0.81 | RAPGEF3 (0.33) | CCR1 | |
| SCHEMBL21956246 | 0.81 | AKR1B1 (0.41) | FFAR1GPR17KDM4ECYP2D6 | |
| SCHEMBL21631905 | 0.81 | PTGFR (0.32) | PTGFRCCR1FFAR1FFAR4CYP2D6 | |
| SCHEMBL20534952 | 0.78 | PTGFR (0.41) | PTGFRFFAR4GPR17FABP4KDM4E | |
| SCHEMBL21632375 | 0.78 | CES2 (0.38) | PTGFRCCR1FFAR1FFAR4CYP2D6 | |
| SCHEMBL21632180 | 0.77 | MDM2 (0.38) | PTGFRFFAR1FFAR4 | |
| SCHEMBL21632069 | 0.76 | PTGFR (0.43) | PTGFRGPR17CYP2D6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-05 | — | — | US | disclosed |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031775-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, NAT1, EPX | PTGFR 1050/4885CCR1 543/4885FFAR1 781/4885 |
| US-20200157073-A1 | SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | AADAC, ARG2, GOT2 | PTGFR 1184/4885CCR1 1073/4885FFAR1 1059/4885 |
| US-11149018-B2 | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | AADAC, ARG2, GOT2 | PTGFR 1184/4885CCR1 1073/4885FFAR1 1059/4885 |
| US-11136296-B2 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | AADAC, NAT1, EPX | PTGFR 1050/4885CCR1 543/4885FFAR1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.